摘要
前列腺癌是老年男性常见的恶性肿瘤之一。化疗是治疗转移性去势抵抗性前列腺癌的有效方法,但多数患者在经过6~8个周期的全身化疗后会出现耐药,中位生存期不足1年。因此,阐明去势抵抗性前列腺癌与化疗耐药的相关机制显得十分重要。我们将围绕雄激素受体信号通路、微小RNA、肿瘤微环境、肿瘤干细胞以及相关分子事件,对前列腺癌化疗耐药的机制研究进展进行综述。
Prostate cancer is one of the most common malignancies in old males.While chemotherapy remains an effective method for metastatic castration resistant prostate eancer (mCRPC),most patients develop chemo -resist-ance with median survival less than 1 year after six to eight cycles of systematic chemotherapy.Therefore,it is very important to elucidate the mechanisms of CRPC and chemotherapy resistance.This article is to focus on the androgen receptor signaling pathway,micro -RNA,tumor microenvironment,cancer stem cells as well as related molecular events,and to summarize the research orozress.
作者
徐佩行
沈益君
Xu Peihang;Shen Yijun(Department of Urology,Fudan University Shanghai Cancer Center and Department of Oncology,Fudan University, Shanghai 200032,China)
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2019年第1期190-193,共4页
Chinese Journal of Experimental Surgery
基金
国家自然科学基金面上项目(81572531).
关键词
去势抵抗性前列腺癌
化疗耐药
机制
Castration resistant prostate cancer
Chemotherapy resistance
Mechanism
